Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cyclophosphamide + Doxorubicin + JNJ-87801493 + JNJ-95566692 + Prednisone + Vincristine Sulfate |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
| Doxorubicin | Adriamycin | Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin | Chemotherapy - Anthracycline 13 TOPO2 inhibitor 5 | Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
| JNJ-87801493 | JNJ 87801493|JNJ87801493 | CD20 Antibody 29 CD28 Antibody 14 | JNJ-87801493 is a bispecific antibody targeting CD20 on B-cells and CD28 on T-cells, which potentially enhances T-cell activation and inhibits tumor growth (Blood (2024) 144 (Supplement 1): 1408). | |
| JNJ-95566692 | JNJ95566692|JNJ 95566692 | CD20 Antibody 29 CD3 Antibody 128 | Limited information is currently available on JNJ-95566692, a putative trispecific antibody targeting CD79b, MS4A1 (CD20), and CD3 (Feb 2026). | |
| Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). | |
| Vincristine Sulfate | Oncovin | 22-Oxovincaleukoblastine|vincristine | Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07308132 | Phase I | Cyclophosphamide + Doxorubicin + JNJ-95566692 + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + JNJ-87801493 + JNJ-95566692 + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + JNJ-95566692 + Prednisone + Rituximab + Vincristine Sulfate JNJ-87801493 + JNJ-95566692 + Lenalidomide JNJ-95566692 + Lenalidomide Gemcitabine + JNJ-87801493 + JNJ-95566692 + Oxaliplatin + Rituximab Gemcitabine + JNJ-95566692 + Oxaliplatin + Rituximab JNJ-87801493 + JNJ-95566692 + Loncastuximab tesirine-lpyl JNJ-95566692 + Loncastuximab tesirine-lpyl JNJ-87801493 JNJ-87801493 + JNJ-95566692 JNJ-95566692 Cyclophosphamide + Doxorubicin + JNJ-87801493 + JNJ-95566692 + Polatuzumab vedotin-piiq + Prednisone + Rituximab | A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies | Recruiting | TUR | FRA | ESP | BEL | AUS | 0 |
CKB BOOST